These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 32128854)

  • 1. Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease.
    Spencer S; Wheeler-Jones C; Elliott J
    J Vet Pharmacol Ther; 2020 May; 43(3):243-267. PubMed ID: 32128854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
    Epstein M
    Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
    Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
    Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
    Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.
    Kawarazaki W; Nagase M; Yoshida S; Takeuchi M; Ishizawa K; Ayuzawa N; Ueda K; Fujita T
    J Am Soc Nephrol; 2012 Jun; 23(6):997-1007. PubMed ID: 22440899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.
    Nagase M
    Clin Exp Nephrol; 2010 Aug; 14(4):303-14. PubMed ID: 20533072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome.
    Shibata S; Fujita T
    Mol Cell Endocrinol; 2012 Mar; 350(2):273-80. PubMed ID: 21820485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor activation as an etiological factor in kidney diseases.
    Ueda K; Nagase M
    Clin Exp Nephrol; 2014 Feb; 18(1):16-23. PubMed ID: 23832326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
    Kolkhof P; Joseph A; Kintscher U
    Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 33358451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury.
    Kiyomoto H; Rafiq K; Mostofa M; Nishiyama A
    J Pharmacol Sci; 2008 Dec; 108(4):399-405. PubMed ID: 19057124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease.
    Nishiyama A
    Hypertens Res; 2019 Mar; 42(3):293-300. PubMed ID: 30523293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
    Nagase M; Matsui H; Shibata S; Gotoda T; Fujita T
    Hypertension; 2007 Nov; 50(5):877-83. PubMed ID: 17875821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ubiquitous mineralocorticoid receptor: clinical implications.
    Hawkins UA; Gomez-Sanchez EP; Gomez-Sanchez CM; Gomez-Sanchez CE
    Curr Hypertens Rep; 2012 Dec; 14(6):573-80. PubMed ID: 22843494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia and chronic kidney disease: Possible mechanisms, therapeutic targets, and relevance to cats.
    Spencer S; Wheeler-Jones C; Elliott J
    Vet J; 2021 Aug; 274():105714. PubMed ID: 34252550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.
    Nishiyama A; Abe Y
    J Pharmacol Sci; 2006 Jan; 100(1):9-16. PubMed ID: 16397374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
    Rafiq K; Hitomi H; Nakano D; Nishiyama A
    J Pharmacol Sci; 2011; 115(1):1-7. PubMed ID: 21186336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
    Barrera-Chimal J; Girerd S; Jaisser F
    Kidney Int; 2019 Aug; 96(2):302-319. PubMed ID: 31133455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.
    Mende CW; Samarakoon R; Higgins PJ
    Am J Nephrol; 2023; 54(1-2):50-61. PubMed ID: 36682353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.